Role of anagrelide in the treatment of thrombocytosis

Annals of Pharmacotherapy

Volumn 33, Issue 10, 1999, Pages

  Brooks, Wesley G ^a,b   Stanley, Dennis D ^c   Goode, Jean Venable R ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b Martha Jefferson Hospital   (United States)

^c Ukrop's Pharmacy   (United States)

Author keywords

Anagrelide; Essential trombocythemia; Thrombocytosis

Indexed keywords

ANAGRELIDE;

ANEMIA; ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG SAFETY; EDEMA; HEADACHE; HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; THROMBOCYTHEMIA; THROMBOCYTOSIS; VERTIGO;

HUMANS; PLATELET AGGREGATION INHIBITORS; QUINAZOLINES; THROMBOCYTOSIS;

EID: 0345363281     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.18384     Document Type: Article

References (10)

1. Anagrelide Study Group. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am J Med 1992;92:69-76.
2. Tefferi A, Silverstein MN. Chronic myeloproliferative diseases. In: Bennet JC, Plum F, eds. Cecil textbook of medicine. 20th ed. Philadelphia: WB Saunders, 1996:922-9.
3. McIntyre KJ, Hoagland HC, Silverstein MN, Petitt RM. Essential thrombocythemia in young adults. Mayo Clin Proc 1991;66:149-54.
4. Tefferi A, Silverstein MN, Hoagland HC. Primary thrombocythemia. Semin Oncol 1995;22:334-40.
5. Spencer CM, Brogden RN. Anagrelide: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of thrombocythemia. Drugs 1994;47:809-82.
6. Fenaux P, Simon M, Caulier MT, Lai JL, Goudemand J, Bauters F. Clinical course of essential thrombocythemia in 147 cases. Cancer 1990;66: 549-56.
7. Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodegheiro F. Incidence and risk factors from thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 1990;8:556-62.
8. Tefferi A, Silverstein M, Petitt R, Mesa R, Solberg L. Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of action, efficacy, toxicity, current indications. Semin Thromb Hemost 1997;23:379-83.
9. Prescribing information. Agrylin (anagrelide hydrochloride). Eatontown, NJ: Roberts Pharmaceutical Corp., 1995.
10. Mazur EM, Rosmarin AG, Sohl PA, Newton JL, Narendran A. Analysis7 of the mechanism of anagrelide induced thrombocythemia in humans. Blood 1992;79:1931-7.